Antiangiogenic activity and pharmacogenomics of medicinal plants from traditional Korean medicine

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Seo, Ean Jeong ^a   Kuete, Victor ^a,b   Kadioglu, Onat ^a   Krusche, Benjamin ^a   Schröder, Sven ^c   Greten, Henry Johannes ^d,e   Arend, Joachim ^a   Lee, Ik Soo ^f   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF DSCHANG   (Cameroon)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF PORTO   (Portugal)

^e Heidelberg School of Chinese Medicine   (Germany)

^f Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOPHORA RACEMOSA EXTRACT; ANGIOGENESIS INHIBITOR; CARYOPTERIS INCANA EXTRACT; CINNAMOMUM JAPONICUM EXTRACT; MESSENGER RNA; PLANT EXTRACT; REYNOUTRIA SACHALNIENSIS EXTRACT; SCHISANDRA CHINENSIS EXTRACT; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACER; ACER MONO; ACER MONO EXTRACT; ADENOPHORA RACEMOSA; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARYOPTERIS INCANA; CINNAMOMUM; CINNAMOMUM JAPONICUM; COMPUTER MODEL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; EURYA JAPONICA; EURYA JAPONICA EXTRACT; FRUIT; GENE EXPRESSION PROFILING; IC 50; KOREAN MEDICINE; MEDICINAL PLANT; MICROARRAY ANALYSIS; MOLECULAR DOCKING; NONHUMAN; PHARMACOGENOMICS; PLANT LEAF; PLANT STEM; PRIORITY JOURNAL; REYNOUTRIA SACHALNIENSIS; SCHISANDRA CHINENSIS;

EID: 84881510821     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/131306     Document Type: Article

References (81)

1. Bhakuni D. S., Bittner M., Marticorena C., Silva M., Weldt E., Melo M. E., Zemelman R., Screening of Chilean plants for antimicrobial activity. Lloydia 1974 37 4 621 632 2-s2.0-0016325750
2. Farnsworth N. R., Akerele O., Bingel A. S., Medicinal plants in therapy. Bulletin of the World Health Organization 1985 63 6 965 981 2-s2.0-0022191565 (Pubitemid 16055431)
3. Feng Y., Wang N., Zhu M., Feng Y., Li H., Tsao S., Recent progress on anticancer candidates in patents of herbal medicinal products. Recent Patents on Food, Nutrition & Agriculture 2011 3 1 30 48 2-s2.0-79955007154
4. Olaku O., White J. D., Herbal therapy use by cancer patients: a literature review on case reports. European Journal of Cancer 2011 47 4 508 514 2-s2.0-79851510937 10.1016/j.ejca.2010.11.018
5. Frass M., Strassl R. P., Friehs H., Müllner M., Kundi M., Kaye A. D., Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review. Ochsner Journal 2012 12 1 45 56 2-s2.0-84858680181
6. Efferth T., Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. Planta Medica 2010 76 11 1143 1154 2-s2.0-77955063009 10.1055/s-0030-1249937
7. Efferth T., Stem cells, cancer stem-like cells, and natural products. Planta Medica 2012 78 10 935 942
8. Sertel S., Plinkert P. K., Efferth T., Natural products derived from traditional Chinese medicine as novel inhibitors of the epidermal growth factor receptor. Combinatorial Chemistry and High Throughput Screening 2010 13 10 849 854 2-s2.0-79951646318 10.2174/138620710793360266
9. Youns M., Hoheisel J. D., Efferth T., Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine. Planta Medica 2010 76 17 2019 2025 2-s2.0-78649904210 10.1055/s-0030-1250432
10. Efferth T., Kaina B., Toxicities by herbal medicines with emphasis to traditional Chinese medicine. Current Drug Metabolism 2011 12 10 989 996 2-s2.0-82255195527 10.2174/138920011798062328
11. Eichhorn T., Efferth T., P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. Journal of Ethnopharmacology 2012 141 2 557 570 2-s2.0-80455174215 10.1016/j.jep.2011.08.053
12. Efferth T., Li P. C. H., Konkimalla V. S. B., Kaina B., From traditional Chinese medicine to rational cancer therapy. Trends in Molecular Medicine 2007 13 8 353 361 2-s2.0-34547179813 10.1016/j.molmed.2007.07.001 (Pubitemid 47126989)
13. Efferth T., Fu Y.-J., Zu Y.-G., Schwarz G., Konkimalla V. S. B., Wink M., Molecular target-guided tumour therapy with natural products derived from Traditional Chinese Medicine. Current Medicinal Chemistry 2007 14 19 2024 2032 2-s2.0-34548634137 10.2174/092986707781368441 (Pubitemid 47578160)
14. Youns M., Hoheisel J. D., Efferth T., Traditional Chinese Medicines (TCMs) for molecular targeted therapies of tumours. Current Drug Discovery Technologies 2010 7 1 37 45 2-s2.0-77951748113 10.2174/157016310791162730
15. Kuete V., Efferth T., Cameroonian medicinal plants: pharmacology and derived natural products. Frontiers in Pharmacology 2010 1 123 1 19
16. Kuete V., Efferth T., Pharmacogenomics of Cameroonian traditional herbal medicine for cancer therapy. Journal of Ethnopharmacology 2011 137 1 752 766 2-s2.0-80052021375 10.1016/j.jep.2011.06.035
17. Khalid H., Abdalla W. E., Abdelgadir H., Opatz T., Efferth T., Gems from traditional north-African medicine: medicinal and aromatic plants from Sudan. Natural Products and Bioprospecting 2012 2 3 92 103
18. Cheong Y. S., Park E. W., Yoo S. M., Use of traditional medicine and folk remedies in hypertensive patients: based on Cheonan practice-based research network. Journal of the Korean Academy of Family Medicine 1998 19 2 141 149
19. Hong C. D., Complementary and alternative medicine in Korea: current status and future prospects. Journal of Alternative and Complementary Medicine 2001 7 supplement 1 S33 S40 2-s2.0-0035686680 (Pubitemid 34072556)
20. Hong M. S., Chun K. H., Song H. J., Park I. W., Attitudes towards complementary and alternative medicine in Suwon city. Korean Journal of Preventive Medicine 1999 32 2 162 169
21. Krenn L., Paper D. H., Inhibition of angiogenesis and inflammation by an extract of red clover (Trifolium pratense L.). Phytomedicine 2009 16 12 1083 1088 2-s2.0-70350580921 10.1016/j.phymed.2009.05.017
22. Wahl O., Oswald M., Tretzel L., Herres E., Arend J., Efferth T., Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Current Medicinal Chemistry 2011 18 21 3136 3155 2-s2.0-79959958353 10.2174/092986711796391570
23. Campa C., Harding S. P., Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Current Drug Targets 2011 12 2 173 181 2-s2.0-79955663810
24. Wang S., Park J. K., Duh E. J., Novel targets against retinal angiogenesis in diabetic retinopathy. Current Diabetes Reports 2012 12 4 355 363
25. Johannessen T. C., Wagner M., Straume O., Bjerkvig R., Eikesdal H. P., Tumor vasculature: the Achilles' heel of cancer? Expert Opinion Therapeutic Targets 2013 17 1 7 20
26. Anfosso L., Efferth T., Albini A., Pfeffer U., Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics Journal 2006 6 4 269 278 2-s2.0-33746531759 10.1038/sj.tpj.6500371 (Pubitemid 44137954)
27. Wittmann J., Kugler W., Kaltner H., Cultivation of the early quail embryo: induction of embryogenesis under in vitro conditions. The Journal of Experimental Zoology 1987 244 1 325 328 2-s2.0-0023065799 (Pubitemid 18068085)
28. D'Arcy P. F., Howard E. M., A new anti-inflammatory test, utilizing the chorio-allantoic membrane of the chick embryo. British Journal of Pharmacology 1967 29 3 378 387 2-s2.0-0014068131
29. Marchesan M., Paper D. H., Hose S., Franz G., Investigations of the anti- inflammatory activity of liquid extracts of Plantago lanceolata L. Phytotherapy Research 1998 12 S1 33 34
30. Kuete V., Krusche B., Youns M., Voukeng I., Fankam A. G., Tankeo S., Lacmata S., Efferth T., Cytotoxicity of some Cameroonian spices and selected medicinal plant extracts. Journal of Ethnopharmacology 2011 134 3 803 812 2-s2.0-79954415842 10.1016/j.jep.2011.01.035
31. Scherf U., Ross D. T., Waltham M., Smith L. H., Lee J. K., Tanabe L., Kohn K. W., Reinhold W. C., Myers T. G., Andrews D. T., Scudiero D. A., Eisen M. B., Sausville E. A., Pommier Y., Botstein D., Brown P. O., Weinstein J. N., A gene expression database for the molecular pharmacology of cancer. Nature Genetics 2000 24 3 236 244 2-s2.0-0034088857 10.1038/73439 (Pubitemid 30132190)
32. Amundson S. A., Do K. T., Vinikoor L. C., Lee R. A., Koch-Paiz C. A., Ahn J., Reimers M., Chen Y., Scudiero D. A., Weinstein J. N., Trent J. M., Bittner M. L., Meltzer P. S., Fornace A. J. Jr., Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Research 2008 68 2 415 424 2-s2.0-39449113309 10.1158/0008-5472.CAN-68-4-COR4 (Pubitemid 351272248)
33. Efferth T., Herrmann F., Tahrani A., Wink M., Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. Phytomedicine 2011 18 11 959 969 2-s2.0-80051887433 10.1016/j.phymed.2011.06.008
34. Peale F. V. Jr., Gerritsen M. E., Gene profiling techniques and their application in angiogenesis and vascular development. Journal of Pathology 2001 195 1 7 19 2-s2.0-0034812355 10.1002/path.888 (Pubitemid 32899041)
35. Morris G. M., Ruth H., Lindstrom W., Sanner M. F., Belew R. K., Goodsell D. S., Olson A. J., Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009 30 16 2785 2791 2-s2.0-70349932423 10.1002/jcc.21256
36. Efferth T., Kahl S., Paulus K., Adams M., Rauh R., Boechzelt H., Hao X., Kaina B., Bauer R., Phytochemistry and pharmacogenomics of natural products derived from traditional chinese medicine and chinese materia medica with activity against tumor cells. Molecular Cancer Therapeutics 2008 7 1 152 161 2-s2.0-38349163634 10.1158/1535-7163.MCT-07-0073
37. Efferth T., Herrmann F., Tahrani A., Wink M., Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. Phytomedicine 2011 18 11 959 969 2-s2.0-80051887433 10.1016/j.phymed.2011.06.008
38. Efferth T., Oesch F., Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochemical Pharmacology 2004 68 1 3 10 2-s2.0-2942624053 10.1016/j.bcp.2004.03.003 (Pubitemid 38746536)
39. Efferth T., Microarray-based prediction of cytotoxicity of tumor cells to cantharidin. Oncology Reports 2005 13 3 459 463 2-s2.0-15044363650
40. Sertel S., Tome M., Briehl M. M., Factors determining sensitivity and resistance of tumor cells to arsenic trioxide. PLoS ONE 2012 7 5 e35584
41. Kwak H.-J., Park M.-J., Park C.-M., Moon S.-I., Yoo D.-H., Lee H.-C., Lee S.-H., Kim M.-S., Lee H.-W., Shin W.-S., Park I.-C., Rhee C. H., Hong S.-I., Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. International Journal of Cancer 2006 118 11 2711 2720 2-s2.0-33646337670 10.1002/ijc.21641 (Pubitemid 43673348)
42. Kaneshiro T., Morioka T., Inamine M., Kinjo T., Arakaki J., Chiba I., Sunagawa N., Suzui M., Yoshimi N., Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. European Journal of Pharmacology 2006 553 1-3 46 53 2-s2.0-33751188286 10.1016/j.ejphar.2006.09.026 (Pubitemid 44779599)
43. Khan A. A., Dace D. S., Ryazanov A. G., Kelly J., Apte R. S., Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. American Journal of Pathology 2010 177 1 481 492 2-s2.0-77954600273 10.2353/ajpath.2010.090836
44. Wang H., Zhou H., Zou Y., Liu Q., Guo C., Gao G., Shao C., Gong Y., Resveratrol modulates angiogenesis through the GSK3 β / β -catenin/TCF-dependent pathway in human endothelial cells. Biochemical Pharmacology 2010 80 9 1386 1395 2-s2.0-77956652390 10.1016/j.bcp.2010.07.034
45. Jones S. B., DePrimo S. E., Whitfield M. L., Brooks J. D., Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiology Biomarkers and Prevention 2005 14 3 596 604 2-s2.0-16844370130 10.1158/1055-9965.EPI-04-0398 (Pubitemid 40489201)
46. Fu Z.-Y., Han J.-X., Huang H.-Y., Effects of emodin on gene expression profile in small cell lung cancer NCI-H446 cells. Chinese Medical Journal 2007 120 19 1710 1715 2-s2.0-35348962760 (Pubitemid 47603962)
47. Whyte L., Huang Y.-Y., Torres K., Mehta R. G., Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Research 2007 67 24 12007 12017 2-s2.0-37549003691 10.1158/0008-5472.CAN-07-2464
48. Wittmann J., Kugler W., Kaltner H., Cultivation of the early quail embryo: induction of embryogenesis under in vitro conditions. Journal of Experimental Zoology 1987 244 1 325 328 2-s2.0-0023065799 (Pubitemid 18068085)
49. Chopra R. N., Nayar S. L., Chopra I. C., Glossary of Indian Medicinal Plants (Including the Supplement) 1986 New Delhi, India Council of Scientific and Industrial Research
50. Crawford S. E., Mavroudis C., Backer C. L., Huang X., Mu Y., Volpert O. V., Stellmach V., Pahl E., Huang L., Captopril suppresses Post-transplantation angiogenic activity in rat allograft coronary vessels. Journal of Heart and Lung Transplantation 2004 23 6 666 673 2-s2.0-2642564296 10.1016/j.healun.2003.07. 010 (Pubitemid 38721434)
51. Peifer C., Dannhardt G., A novel quantitative chick embryo assay as an angiogenesis model using digital image analysis. Anticancer Research 2004 24 3 A 1545 1551 2-s2.0-3242724199 (Pubitemid 38954675)
52. Kuete V., Seo E. J., Krusche B., Cytotoxicity and pharmacogenomics of medicinal plants from traditional Korean medicine. Evidence-Based Complementary Alternative Medicine 2013
53. Weinstein J. N., Myers T. G., O'Connor P. M., Friend S. H., Fornace A. J. Jr., Kohn K. W., Fojo T., Bates S. E., Rubinstein L. V., Anderson N. L., Buolamwini J. K., Van Osdol W. W., Monks A. P., Scudiero D. A., Sausville E. A., Zaharevitz D. W., Bunow B., Viswanadhan V. N., Johnson G. S., Wittes R. E., Paull K. D., An information-intensive approach to the molecular pharmacology of cancer. Science 1997 275 5298 343 349 2-s2.0-0031035181 10.1126/science.275. 5298.343 (Pubitemid 27051604)
54. Holbeck S., Chang J., Best A. M., Bookout A. L., Mangelsdorf D. J., Martinez E. D., Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. Molecular Endocrinology 2010 24 6 1287 1296 2-s2.0-77954830442 10.1210/me.2010-0040
55. Covell D. G., Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen. PLoS ONE 2012 7 10 e44631
56. Wan P., Li Q., Larsen J. E., Prediction of drug efficacy for cancer treatment based on comparative analysis of chemosensitivity and gene expression data. Bioorganic & Medicinal Chemistry 2012 20 1 167 176
57. Efferth T., Sauerbrey A., Halatsch M.-E., Ross D. D., Gebhart E., Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology 2003 367 1 56 67 2-s2.0-0037280015 10.1007/s00210-002-0632-0 (Pubitemid 36207682)
58. Radha K. S., Madhyastha H. K., Nakajima Y., Omura S., Maruyama M., Emodin upregulates urokinase plasminogen activator, plasminogen activator inhibitor-1 and promotes wound healing in human fibroblasts. Vascular Pharmacology 2008 48 4-6 184 190 2-s2.0-43449124394 10.1016/j.vph.2008.02.002
59. Ok S., Kim S. M., Kim C., Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4. Immunopharmacology and Immunotoxicology 2012 34 5 768 778
60. Lu Y., Zhang J., Qian J., The effect of emodin on VEGF receptors in human colon cancer cells. Cancer Biotherapy and Radiopharmaceuticals 2008 23 2 222 228 2-s2.0-43049142274 10.1089/cbr.2007.0425 (Pubitemid 351630183)
61. Fang J., Xia C., Cao Z., Zheng J. Z., Reed E., Jiang B.-H., Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. The FASEB Journal 2005 19 3 342 353 2-s2.0-14644432362 10.1096/fj.04-2175com (Pubitemid 40316522)
62. Liu L.-Z., Fang J., Zhou Q., Hu X., Shi X., Jiang B.-H., Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Molecular Pharmacology 2005 68 3 635 643 2-s2.0-23944521126 10.1124/mol.105. 011254 (Pubitemid 41206017)
63. Kim B. R., Jeon Y. K., Nam M. J., A mechanism of apigenin-induced apoptosis is potentially related to anti-angiogenesis and anti-migration in human hepatocellular carcinoma cells. Food and Chemical Toxicology 2011 49 7 1626 1632 2-s2.0-79957639518 10.1016/j.fct.2011.04.015
64. Lamy S., Akla N., Ouanouki A., Lord-Dufour S., Béliveau R., Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Experimental Cell Research 2012 318 13 1586 1596 2-s2.0-84860576204 10.1016/j.yexcr.2012.04.004
65. Igura K., Ohta T., Kuroda Y., Kaji K., Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Letters 2001 171 1 11 16 2-s2.0-0035964450 10.1016/S0304-3835(01)00443-8 (Pubitemid 32727351)
66. Bråkenhielm E., Cao R., Cao Y., Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. The FASEB Journal 2001 15 10 1798 1800 2-s2.0-0035430177
67. Garvin S., Öllinger K., Dabrosin C., Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Letters 2006 231 1 113 122 2-s2.0-28844451969 10.1016/j.canlet.2005.01.031 (Pubitemid 41779459)
68. Lin M.-T., Yen M.-I., Lin C.-Y., Kuo M.-L., Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of src-dependent vascular endothelial cadherin tyrosine phosphorylation. Molecular Pharmacology 2003 64 5 1029 1036 2-s2.0-0142210188 10.1124/mol.64.5.1029 (Pubitemid 37310735)
69. Fukuda S., Kaga S., Zhan L., Bagchi D., Das D. K., Bertelli A., Maulik N., Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochemistry and Biophysics 2006 44 1 43 49 2-s2.0-30744441162 10.2303/jecho.4.43 (Pubitemid 43099570)
70. Yu H.-B., Zhang H.-F., Zhang X., Li D.-Y., Xue H.-Z., Pan C.-E., Zhao S.-H., Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism. Hepato-Gastroenterology 2010 57 102-103 1241 1246 2-s2.0-79251543646
71. Mikuła-Pietrasik J., Kuczmarska A., Kucińska M., Murias M., Wierzchowski M., Winckiewicz M., Staniszewski R., Breborowicz A., Ksiazek K., Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8. Angiogenesis 2012 15 3 361 376 2-s2.0-84858726103 10.1007/s10456-012-9266-0
72. Yang S. H., Kim J. S., Oh T. J., Kim M. S., Lee S. W., Woo S. K., Cho H. S., Choi Y. H., Kim Y. H., Rha S. Y., Chung H. C., An S. W., Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. International Journal of Oncology 2003 22 4 741 750 2-s2.0-0348052717
73. Huang Z., Chen G., Shi P., Effects of emodin on the gene expression profiling of human breast carcinoma cells. Cancer Detection and Prevention 2009 32 4 286 291 2-s2.0-60749104674 10.1016/j.cdp.2008.12.003
74. Cai J., Zhao X.-L., Liu A.-W., Nian H., Zhang S.-H., Apigenin inhibits hepatoma cell growth through alteration of gene expression patterns. Phytomedicine 2011 18 5 366 373 2-s2.0-79952737116 10.1016/j.phymed.2010.08.006
75. Efferth T., Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Current Medicinal Chemistry 2012 19 33 5735 5744
76. Wagner H., Multitarget therapy-the future of treatment for more than just functional dyspepsia. Phytomedicine 2006 13 supplement 5 122 129 2-s2.0-33751319652 10.1016/j.phymed.2006.03.021 (Pubitemid 44816466)
77. Efferth T., Koch E., Complex interactions between Phytochemicals. The Multi-Target Therapeutic concept of Phytotherapy. Current Drug Targets 2011 12 1 122 132 2-s2.0-78650912735 10.2174/138945011793591626
78. Bhargava P., Robinson M. O., Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Current Oncology Reports 2011 13 2 103 111 2-s2.0-79955829332 10.1007/s11912-011-0154-3
79. Choueiri T. K., Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Current Opinion in Investigational Drugs 2008 9 6 658 671 2-s2.0-44649151405 (Pubitemid 351777169)
80. Kelly R. J., Rixe O., Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Targeted Oncology 2009 4 4 297 305 2-s2.0-72449131348 10.1007/s11523-009-0126-9
81. Newman D. J., Cragg G. M., Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal of Natural Products 2012 75 3 311 335 2-s2.0-84858308226 10.1021/np200906s